Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK.
作者信息
Nadesalingam Angalee, Cantoni Diego, Wells David A, Aguinam Ernest T, Ferrari Matteo, Smith Peter, Chan Andrew, Carnell George, Ohlendorf Luis, Einhauser Sebastian, George Charlotte, Wagner Ralf, Temperton Nigel, Castillo-Olivares Javier, Baxendale Helen, Heeney Jonathan L
机构信息
Laboratory of Viral Zoonotics, University of Cambridge, Cambridge CB3 OES, UK.
Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Medway, UK.
出版信息
Lancet Microbe. 2021 Sep;2(9):e416-e418. doi: 10.1016/S2666-5247(21)00157-9. Epub 2021 Jun 28.
Abstract
摘要
相似文献
1
Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK.
Lancet Microbe. 2021 Sep;2(9):e416-e418. doi: 10.1016/S2666-5247(21)00157-9. Epub 2021 Jun 28.
2
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.
Lancet Microbe. 2022 Jan;3(1):e21-e31. doi: 10.1016/S2666-5247(21)00275-5. Epub 2021 Nov 9.
3
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
4
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
Lancet Microbe. 2022 May;3(5):e348-e356. doi: 10.1016/S2666-5247(22)00036-2. Epub 2022 Mar 23.
5
SARS-CoV-2 neutralising antibody therapies: Recent advances and future challenges.
Rev Med Virol. 2023 Sep;33(5):e2464. doi: 10.1002/rmv.2464. Epub 2023 Jun 15.
6
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients.
Lancet. 2021 Sep 18;398(10305):1038-1041. doi: 10.1016/S0140-6736(21)01854-7. Epub 2021 Aug 13.
7
Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
Clin Immunol. 2021 Nov;232:108871. doi: 10.1016/j.clim.2021.108871. Epub 2021 Oct 4.
8
Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers.
Clin Infect Dis. 2022 Mar 1;74(4):707-710. doi: 10.1093/cid/ciab492.
9
Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
mSphere. 2022 Aug 31;7(4):e0016922. doi: 10.1128/msphere.00169-22. Epub 2022 Jul 5.
10
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
Transfus Med. 2021 Jun;31(3):167-175. doi: 10.1111/tme.12746. Epub 2020 Dec 17.
引用本文的文献
1
Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population.
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241239202. doi: 10.1177/03946320241239202.
2
Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.
J Allergy Clin Immunol Glob. 2023 May;2(2):100091. doi: 10.1016/j.jacig.2023.100091. Epub 2023 Mar 15.
3
Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group.
Antibiotics (Basel). 2023 Jan 10;12(1):138. doi: 10.3390/antibiotics12010138.
4
Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.
Viruses. 2022 Aug 30;14(9):1916. doi: 10.3390/v14091916.
5
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study.
J Infect. 2022 Nov;85(5):545-556. doi: 10.1016/j.jinf.2022.09.004. Epub 2022 Sep 9.
6
SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol.
BMJ Open. 2022 May 19;12(5):e061345. doi: 10.1136/bmjopen-2022-061345.
7
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
Nat Commun. 2022 May 13;13(1):2670. doi: 10.1038/s41467-022-30340-5.
8
AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
BMC Med. 2022 Mar 28;20(1):128. doi: 10.1186/s12916-022-02342-z.
9
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Front Immunol. 2021 Dec 17;12:793191. doi: 10.3389/fimmu.2021.793191. eCollection 2021.
10
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
Drug Saf. 2021 Dec;44(12):1247-1269. doi: 10.1007/s40264-021-01131-6. Epub 2021 Nov 5.
本文引用的文献
1
Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes.
Bio Protoc. 2021 Nov 5;11(21):e4236. doi: 10.21769/BioProtoc.4236.
2
The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and sex profile of COVID-19 mortality: A population based ecological study.
Lancet Reg Health Am. 2021 Sep;1:100021. doi: 10.1016/j.lana.2021.100021. Epub 2021 Jul 13.
3
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
Nat Med. 2021 Aug;27(8):1379-1384. doi: 10.1038/s41591-021-01413-7. Epub 2021 Jun 14.
4
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
5
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
Lancet. 2021 May 8;397(10286):1725-1735. doi: 10.1016/S0140-6736(21)00790-X. Epub 2021 Apr 23.
6
Covid-19: Infections fell by 65% after first dose of AstraZeneca or Pfizer vaccine, data show.
BMJ. 2021 Apr 23;373:n1068. doi: 10.1136/bmj.n1068.
7
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell. 2021 May 27;184(11):2939-2954.e9. doi: 10.1016/j.cell.2021.03.055. Epub 2021 Mar 30.
8
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell. 2021 Apr 29;184(9):2348-2361.e6. doi: 10.1016/j.cell.2021.02.037. Epub 2021 Feb 23.
9
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
10
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.
Nature. 2021 May;593(7858):270-274. doi: 10.1038/s41586-021-03426-1. Epub 2021 Mar 15.
Zotero 插件